VIVUS, Inc. (VVUS): An Obese Proxy Fight

Page 2 of 2

But investors are in a bit of pickle because it’s entirely possible that First Manhattan will dump its shares if it doesn’t win the proxy battle. That won’t be pretty.

Management might be best off looking at how Biogen Idec Inc. (NASDAQ:BIIB) handled its proxy fight with investor Carl Icahn, giving him a seat on the board — filled by one of his appointees, Eric Rowinsky — to get Icahn to remove his slate of proposed board members.

A little bit of compromise could go a long way toward grabbing the checkered flag with enough gas to fight against Arena Pharmaceuticals, Inc. (NASDAQ:ARNA).

The article An Obese Proxy Fight originally appeared on Fool.com.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2